Skip to content
WeighLab
Menu
Ranked #428 · Grade C

VyrarX review

VyraRx is a GLP-1 telehealth service offering compounded semaglutide and tirzepatide with physician oversight, claiming coverage in 47 states and displaying a LegitScript seal.

Visit VyrarX Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Compounded only

Pricing verified August 2026

The Index scorecard

VyrarX scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month45/100
Price Transparency54/100
Nationwide Access24/100
Formulation Options40/100
Clinical Oversight85/100
Contract Flexibility55/100

Where the value is

  • Clear headline pricing for both semaglutide and tirzepatide
  • Claims broad 47-state coverage
  • LegitScript seal displayed on the homepage
  • Explicit physician-review language for every prescription

The tradeoffs

  • No named medical director or clinical leadership anywhere on the public site
  • No named compounding pharmacy partner disclosed
  • 'From' pricing likely reflects only the lowest dose tier -- no full pricing ladder published
  • Several expected subpages (/pricing, /faq, /how-it-works) returned 404, limiting transparency

The bottom line

Best for: Shoppers comparing headline GLP-1 starting prices who don't need pharmacy/clinical-leadership transparency up front. VyraRx is a GLP-1 telehealth service offering compounded semaglutide and tirzepatide with physician oversight, claiming coverage in 47 states and displaying a LegitScript seal.

Ranked #428 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to VyrarX.

The 24 programs nearest this one

Pricing, states and verification reflect VyrarX's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on VyrarX's site. Not medical advice; see our disclosure.

← Back to the value leaderboard